Patents by Inventor Weiduan Xu

Weiduan Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7566546
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Sacha J. Holland, Weiduan Xu
  • Patent number: 7527936
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: May 5, 2009
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Weiduan Xu, Sacha J. Holland, James Lorens
  • Patent number: 7485414
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: February 3, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
  • Patent number: 7419779
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: September 2, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
  • Patent number: 7244576
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: July 17, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger
  • Publication number: 20060264392
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic adds, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: September 2, 2003
    Publication date: November 23, 2006
    Inventors: James Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
  • Publication number: 20050250163
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: February 16, 2005
    Publication date: November 10, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Sacha Holland, Weiduan Xu
  • Publication number: 20050208472
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: January 13, 2005
    Publication date: September 22, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Weiduan Xu, Sacha Holland, James Lorens
  • Publication number: 20040053233
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 18, 2004
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
  • Publication number: 20030176333
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding contactin associated protein 3 (CASPR3), which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of CASPR3; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: March 18, 2002
    Publication date: September 18, 2003
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger
  • Publication number: 20020156003
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.
    Type: Application
    Filed: August 21, 2001
    Publication date: October 24, 2002
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger